Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about INDP, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| TLR Agonist Decoy20 | Solid Tumor, Adult | Phase 1/2 · NCT05651022 | Active not recruiting |
Also used in these trials (approved or third-party drugs, not INDP's own candidates): Tislelizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
INDP holds $11.6M in cash and short-term investments (as of Jun 30, 2026) and burns about $4.5M/quarter from operations, an estimated runway of 7.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 35 · Moderate
As a result of these uncertainties, there is substantial doubt about the Company’s ability to continue as a going concern.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when INDP files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for INDP and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →